C WorldWide Group Holding A S Reduces Stake in bluebird bio, Inc. (NASDAQ:BLUE)
C WorldWide Group Holding A S lowered its position in bluebird bio, Inc. (NASDAQ:BLUE) by 14.6% during the second quarter, Holdings Channel reports. The fund owned 2,100 shares of the biotechnology company’s stock after selling 358 shares during the period. C WorldWide Group Holding A S’s holdings in bluebird bio were worth $221,000 at the end of the most recent reporting period.
Several other hedge funds also recently made changes to their positions in the company. Bank of Montreal Can boosted its stake in shares of bluebird bio by 118.9% in the second quarter. Bank of Montreal Can now owns 1,677 shares of the biotechnology company’s stock worth $176,000 after buying an additional 911 shares during the last quarter. Affinity Investment Advisors LLC bought a new stake in shares of bluebird bio during the second quarter worth $246,000. First Mercantile Trust Co. boosted its stake in shares of bluebird bio by 14.4% in the first quarter. First Mercantile Trust Co. now owns 2,897 shares of the biotechnology company’s stock worth $263,000 after buying an additional 365 shares during the last quarter. Berkeley Capital Partners LLC bought a new stake in shares of bluebird bio during the first quarter worth $282,000. Finally, Teacher Retirement System of Texas bought a new stake in shares of bluebird bio during the first quarter worth $291,000.
bluebird bio, Inc. (NASDAQ BLUE) opened at 93.95 on Friday. The firm’s market capitalization is $4.28 billion. bluebird bio, Inc. has a 12 month low of $37.05 and a 12 month high of $123.75. The stock’s 50 day moving average price is $98.52 and its 200 day moving average price is $90.12.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.66) by $0.07. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. The company had revenue of $16.70 million during the quarter, compared to the consensus estimate of $6.29 million. During the same quarter last year, the firm earned ($1.59) EPS. The business’s revenue for the quarter was up 977.4% on a year-over-year basis. Equities research analysts expect that bluebird bio, Inc. will post ($6.78) earnings per share for the current fiscal year.
BLUE has been the topic of a number of research reports. Maxim Group upgraded bluebird bio from a “hold” rating to a “buy” rating and set a $100.00 price target on the stock in a research report on Friday, June 2nd. BTIG Research restated a “buy” rating and issued a $112.00 target price on shares of bluebird bio in a research report on Thursday, June 1st. Standpoint Research assumed coverage on bluebird bio in a research report on Tuesday, May 30th. They issued a “buy” rating and a $110.00 target price on the stock. BMO Capital Markets restated a “buy” rating and issued a $108.00 target price on shares of bluebird bio in a research report on Tuesday, June 6th. Finally, Janney Montgomery Scott raised their target price on bluebird bio from $81.00 to $125.00 and gave the company a “buy” rating in a research report on Wednesday, June 7th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $100.66.
In related news, insider David Davidson sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $90.00, for a total value of $90,000.00. Following the completion of the transaction, the insider now owns 18,177 shares in the company, valued at approximately $1,635,930. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Daniel Lynch sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $80.00, for a total transaction of $160,000.00. Following the completion of the transaction, the director now owns 3,400 shares of the company’s stock, valued at approximately $272,000. The disclosure for this sale can be found here. Insiders sold a total of 77,856 shares of company stock valued at $8,093,145 in the last 90 days. 3.90% of the stock is currently owned by corporate insiders.
bluebird bio Company Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio, Inc. (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.